Mylan will pay $30 million to settle US charges it misled investors about probes of EpiPen payments under a federal health program, a US securities regulator announced Friday. Mylan settled the case without admitting or denying the allegations. The charges concern Mylan’s statements to investors in 2015 and 2016, a period when the drug company was criticized in the media and in Congress for massive price increases of more than 500 percent for EpiPen, a lifesaving allergy medication. In the federal Medicaid program, Mylan had categorized EpiPen as a generic drug, a classification that allowed it to pay lower rebates to the government than if the drug had been called a branded drug. US officials administering Medicaid contested this classification and the matter was also probed by the US Department of Justice. In October 2016, Mylan agreed to pay $465 million to settle the Justice Department charges that it overbilled Medicaid for the EpiPen medication. The SEC contended that Mylan kept investors in the dark about the possible liability prior to the settlement. By the third quarter of 2015, Mylan “knew or should have known” that a material loss connected to the probes was “reasonably possible,” the SEC said in… Read full this story
- Watchdog now has 10 probes into Facebook
- 30 officials to face trial in Barcelona over role in independence referendum
- Germany fines BMW 8.5 mn euros over diesel emissions
- What you need to consider before taking a settlement agreement
- SFO abandons probes into Rolls-Royce and Glaxo
- Totally Unbiased? Possible Conflict of Interest Dogs Football Leaks Probe
- Police probe motorhome fraud claims
- Man City blast 'false accusations' as UEFA open spending rules probe
- 5,000 interviews, 200 indictments, and ONE Mueller report
- Cardiff council using 'gagging orders' on former staff
Mylan in $30 mn US settlement over EpiPen probe disclosures have 273 words, post on en.rfi.fr at September 27, 2019. This is cached page on Law Breaking News. If you want remove this page, please contact us.